Clinical Challenge: Vomiting and Testicle Pain
A patient with a history of HIV presents to the ED with a 3- to 4-week history of vomiting and testicle pain. Can you make the diagnosis?
RSS News Feed
Latest
Racial Disparities in Radiotherapy Regimens for Prostate and Breast Cancer
Black cancer patients are less likely than their White counterparts to receive shorter radiotherapy regimens, a study suggests.
Consolidation Regimen Deemed “Highly Active” in Relapsed/Refractory Hodgkin Lymphoma
Consolidation with up to 8 cycles of brentuximab vedotin plus nivolumab appears active in high-risk, relapsed/refractory Hodgkin lymphoma.
Serial SBRT Potentially Beneficial in Oligometastatic Prostate Cancer
Serial stereotactic body radiation therapy directed by PET using novel radiotracers may offer clinical benefits in patients with oligometastatic prostate cancer.
Convection-Enhanced Delivery of Topotecan Active in Glioblastoma
Chronic convection-enhanced delivery of topotecan was feasible and well tolerated in patients with recurrent glioblastoma.
Enzalutamide, Abiraterone Compared for mCRPC With Comorbidities
Patients with comorbidities are not routinely included in clinical trials.
Increase Seen in Years of Life Lost Per COVID-19 Death in 2021
From 2020 to 2021, COVID-19-related deaths increased among younger people.
Cancer-Related Mortality Tied to Residential Segregation
Residential racial and economic segregation across US counties is associated with higher cancer mortality, a study suggests.
Long-Term Survival With First-Line Nivolumab/Ipilimumab in NSCLC
More than one-third of patients with non-small cell lung cancer treated upfront with nivolumab plus ipilimumab were alive at 3 years.
ctDNA Surveillance Proves Challenging in Triple-Negative Breast Cancer
Using ctDNA testing to predict recurrence and guide therapy in triple-negative breast cancer is challenging, according to researchers.
Risk of Uterine Cancers Increased in Breast Cancer Patients Treated With Tamoxifen
After adjustment for confounding variables, the risk of endometrial cancer was increased almost 4-fold with tamoxifen treatment.
Remote Assessment of Cognitive Function Feasible With Hematologic Malignancies
Researchers demonstrated the feasibility of remote cognitive assessments in patients with hematologic malignancies.
Ibrutinib Improves Survival vs Chemotherapy in CNS-Involved MCL
Patients with MCL and CNS involvement had superior survival when treated with ibrutinib rather than chemotherapy.
Breast Cancer Survivors Have Increased Risk of Implant-Associated ALCL
Breast cancer survivors have an increased risk of breast implant-associated ALCL, but the absolute risk is “extremely low,” according to researchers.
Incidence of Cervical Cancer on the Rise in Patients Aged 30-34 Years
New data show that, in the last 2 decades, the incidence of cervical cancer in the United States has declined or remained stable for most age groups.
Melanoma Diagnosis Linked to Increased Risk of Prostate Cancer
A more than 2-fold increased risk of prostate cancer was seen for patients whose first melanoma diagnosis was 10 to 15 years before study recruitment.
Post-Cystectomy Long-Term Follow-Up Needed Even If No Sign of Bladder Cancer
Recurrence of bladder cancer after radical cystectomy can occur up to 4 years after surgery, a study suggests.
Adding Gilteritinib to Azacitidine Does Not Improve OS, EFS in Newly Diagnosed AML
Adding gilteritinib to azacitidine did not improve survival outcomes in patients with newly diagnosed, FLT3-mutated acute myeloid leukemia.
Significant Treatment Attrition Seen in Multiple Myeloma
Among patients who did not undergo autologous stem cell transplant, 52.7% advanced to second-line treatment.
Prior Authorization Linked to Cancer Progression and Death
The prior authorization process can delay cancer care, leading to disease progression and death, according to a survey of ASCO members.
NSCLC Driving Increase in Stage I Lung Cancer Diagnoses
The incidence of stage I lung cancer increased between 2010 and 2017, according to data from more than 1.4 million US patients with lung cancer.
Zanubrutinib May Produce Better Outcomes Than Ibrutinib in Rel/Ref CLL, SLL
Zanubrutinib may produce superior outcomes to ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Robotic Resection Cuts Perioperative Morbidity With Liver Cancer
Patients who underwent robotic liver resection had shorter hospital stays and were less likely to be admitted to the ICU than patients who underwent open liver resection.
QOL Up With Pembrolizumab vs Ipilimumab, HDI in Resected Melanoma
Adjuvant pembrolizumab improved quality of life when compared with ipilimumab or high-dose interferon α 2b.
FDA Passes on Poziotinib for NSCLC With HER2 Exon 20 Insertions
The FDA has issued a complete response letter to Spectrum Pharmaceuticals regarding the new drug application for poziotinib.
Accredited Hospitals Fail to Disclose Costs of Common Cancer Surgeries
Roughly half of hospitals accredited by the ACS-CoC failed to disclose the cost of 5 common cancer surgeries, researchers found.
Dendritic Cell Vaccine Improves Upon Standard Care for Glioblastoma
Adding an autologous tumor lysate-loaded dendritic cell vaccine to standard care improves survival in patients with glioblastoma, a phase 3 study suggests.
Pediatric Cancer Survivors Experience Premature Aging
Young adult survivors of pediatric cancer experience significant premature aging, a retrospective study suggests.
Homeopathic Add-On Improves QOL, Survival in Non-Small Cell Lung Cancer
Homeopathic treatment may improve quality of life and survival among patients with stage III-IV non-small cell lung cancer who are receiving chemotherapy.
Adults Lack Knowledge About Signs of Pancreatic Cancer
In a survey of more than 1000 adults, 83% said they are unaware of the signs or symptoms of pancreatic cancer.
Registry Data Quantify 5-Year Survival in Lower-Risk MDS
About 40% of patients with lower-risk myelodysplastic syndromes die of the disease within 5 years, a study suggests.
Medicine vs Food: The Patient Care Dilemma of Financial Toxicity
Physicians are calling on colleagues to bring up the cost of care and its potential impact when discussing treatment options with patients.
AEs Related to Antibody-Drug Conjugates Most Common in Breast Cancer
Researchers have characterized treatment-related adverse events associated with antibody-drug conjugates in clinical trials.
Decrease Noted in Lung Cancer Cases Over Past 5 Years
The number of new lung cancer cases decreased 11% over the last 5 years.
Metastasis-Directed Therapy Alone May Treat Solitary Prostate Cancer Recurrence
This is the first study to assess the role of metastasis-directed therapy in solitary metastatic oligorecurrent prostate cancer in the absence of systemic therapy.
Most Pivotal Trials of New Drugs Recruit From Low-, Middle-Income Countries
Researchers found that 56% of cancer trials recruited from low- or middle-income countries.
Aprepitant Better Than Desloratadine for TKI-Induced Pruritus
A prospective study compared aprepitant with desloratadine for the relief of treatment-induced pruritus in patients with lung cancer treated with EGFR-TKIs.
Epcoritamab Granted Priority Review for Relapsed/Refractory Large B-Cell Lymphoma
Epcoritamab is designed to bind to CD3 on T cells and CD20 on B cells, inducing T-cell-mediated killing of CD20+ cells.
Clinical Trial: Trastuzumab-Based Combinations in HER2+ Breast Cancer
Researchers are conducting a phase 2 study to compare trastuzumab-based treatment regimens in patients with advanced HER2+ breast cancer.
Clinical Trial: Capecitabine Plus Cemiplimab in HR+ Metastatic Breast Cancer
Researchers are conducting a phase 1 study to test capecitabine in combination with cemiplimab in patients with HR+ metastatic breast cancer.
Clinical Trial: Can ctDNA Guide Treatment in High-Risk, ER+/HER2- Breast Cancer?
Researchers are conducting a phase 2 study to determine if ctDNA can be used to guide treatment in patients with ER+, HER2- breast cancer at high risk of recurrence.
Clinical Trial: Durvalumab Plus Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer
Researchers are conducting a phase 2 study to test the safety and efficacy of durvalumab in combination with trastuzumab and pertuzumab for HER2-enriched breast cancer.
Are There Factors Associated With Lung Cancer Stage at Diagnosis?
While the rate of late-stage NSCLC diagnosis is improving, more needs to be done to increase survival rates. Are there outside factors that affect the stage at diagnosis, and what can we learn from them?
Medicare Advantage Beneficiaries Have Higher Risk of Death After Cancer Surgeries
Patients with Medicare Advantage insurance plans have an increased risk of death after certain cancer surgeries, a study suggests.
High Rate of Actionable Genetic Variants Found in Colorectal Cancer Patients
Multigene panel testing in a large cohort of patients with colorectal cancer revealed a high rate of clinically actionable genetic variants.
Kaposi Sarcoma Incidence Increasing in Black Men, Decreasing in White Men
The incidence of Kaposi sarcoma is increasing among Black men and decreasing among White men in the United States, a study suggests.
Cancer Screening and Detection Remain Below Prepandemic Levels
Screening for breast, cervical, and colorectal cancer decreased from prepandemic levels in early 2020, rebounded in late 2020, and decreased again in 2021.
FDA Approves Additional Dosing Schedule for Rylaze
The new dosing option was approved based on data from a phase 2/3 trial.
FDA: Patients Should Be Cautious When Using Online Pharmacies to Buy Meds
Red flags include pharmacies that do not require a doctor’s prescription or have a licensed pharmacist to answer questions.
Most Phase 3 Trials of Newly Diagnosed Glioblastoma Show No Improvement in OS
Most recent phase 3 trials of patients with newly diagnosed glioblastoma have shown no significant improvement in overall survival with the experimental treatment.
Deaths on the Rise in Patients With Malignant Brain Tumors
Deaths among patients with primary malignant brain tumors are on the rise in the United States, data suggest.
Risk of COVID-19 and Poor Outcomes Not Increased Among Glioma Patients
Patients with glioma do not have an increased risk of SARS-CoV-2 infection or worse outcomes from COVID-19, a single-center study suggests.
Neuroophthalmological Late Effects Common in Pediatric/Adolescent Medulloblastoma
Children and adolescents with medulloblastoma frequently suffer from neuroophthalmological sequelae, a single-center study suggests.
Predicting Outcomes of Regorafenib in Patients With Recurrent Glioblastoma
Researchers say they have identified a molecular signature that can be used to predict outcomes of regorafenib treatment in patients with recurrent glioblastoma.
Women With Glioblastoma May Be More Likely to Benefit From Immunotherapy
Among glioblastoma patients, women may derive more benefit from immunotherapy than men, research suggests.
Data Show Similar Patterns of Relapse in Standard- and High-Risk Medulloblastoma
Patterns of relapse are similar in patients with standard-risk and high-risk medulloblastoma, a review suggests.
Some Patients With High-Grade Glioma Continue Using Opioids After Perioperative Period
Nearly a third of patients with high-grade glioma who were prescribed opioids after surgery continued to take them beyond the perioperative setting.
Novel Agent Plus Radiotherapy Shows Promise in MGMT-Unmethylated Glioblastoma
VAL-083 in combination with radiotherapy is safe and active in patients with newly diagnosed MGMT-unmethylated glioblastoma, a phase 2 trial suggests.
How to Help Patients Navigate the Disability Claims Process
There are several steps health care providers can take to help patients with CNS cancers navigate the disability application process.
Adding Interferon-α to Temozolomide Prolongs Survival in High-Grade Glioma
Adding interferon-α to adjuvant temozolomide can prolong overall survival in patients with high-grade glioma, a phase 3 trial suggests.
Intracranial Metastasis of Esthesioneuroblastoma May Occur 19 Years After Remission
Recurrence of esthesioneuroblastoma with non-contiguous intracranial metastasis is possible 19 years after remission, a review suggests.
Tovorafenib Elicits Responses in Young Patients With BRAF-Altered Low-Grade Glioma
Tovorafenib produced responses in young patients with progressive or recurrent BRAF-altered low-grade glioma in a phase 2 trial.
Sequence of Ondansetron and Rolapitant Does Not Impact Efficacy in Malignant Glioma
The sequence of treatment with rolapitant and ondansetron does not appear to impact chemoradiation-induced nausea and vomiting.
Palliative Care Consultations Underused, Happen Too Late in High-Grade Glioma
About 1 in 10 patients with high-grade glioma had a palliative care consultation before the end-of-life phase, researchers found.
ART Preferred Over ALND in Sentinel Node-Positive Early Breast Cancer
Axillary radiotherapy can replace axillary lymph node dissection in patients with sentinel node-positive early breast cancer, according to researchers.
Lack of Consensus Regarding Follow-Up After Keratinocyte Carcinoma Treatment
A systematic review of clinical practice guidelines revealed substantial variation in recommendations for follow-up after initial treatment for keratinocyte carcinoma.
Shorter Regimen of Radiotherapy Safe for Soft Tissue Sarcoma
None of the patients had grade 3 or higher acute radiation toxicity.
Even Moderate Exercise Linked to Reduced Mortality After Breast Cancer
Breast cancer survivors who were active or moderately active had significantly reduced risk of death.
Atezolizumab Does Not Improve PFS in Previously Untreated Follicular Lymphoma
Adding atezolizumab to obinutuzumab and bendamustine does not improve progression-free survival and carries an increased risk of adverse events, a study suggests.
FDA Oversight of Clinical Trials Described as “Grossly Inadequate”
An article describes inadequate oversight related to the development of COVID-19 vaccines and predating the pandemic.
Barriers to Access Do Not Fully Explain Disparities in Ovarian Cancer Treatment
Non-Hispanic Black patients are less likely than Hispanic or non-Hispanic White patients to receive guideline-recommended treatment for ovarian cancer.
Adding Tremelimumab and Durvalumab to Chemo Improves PFS, OS in mNSCLC
Adding tremelimumab and durvalumab to chemotherapy improves progression-free survival and overall survival in patients with metastatic non-small cell lung cancer, phase 3 data suggest.
18F-NaF PET-CT More Accurate Than 99mTc-MDP SPECT for Detecting Bone Metastasis
Results of a phase 3 trial suggest 18F-NaF PET-CT is more effective than 99mTc-MDP SPECT for detecting bone metastasis in patients with breast or prostate cancer.
Prolonging Bevacizumab Treatment Does Not Improve PFS or OS in Ovarian Cancer
Fifteen months of bevacizumab should remain the standard for patients with ovarian cancer receiving chemotherapy after cytoreductive surgery, researchers say.
Consolidative Stem Cell Transplant May Improve Outcomes in PTCL
Researchers sought to determine whether patients with PTCL who have a complete response after A+CHP would benefit from SCT.
American Medical Association Pushes for Permanent Use of Standard Time
The yearly switch to daylight saving time has been linked to increased odds for heart problems, accidents, and mood disorders.
SARS-CoV-2 Reinfection Ups Risks for Death, Hospitalization
Reinfection increases the risk of death, hospitalization, and incident sequelae, regardless of vaccination status.
“Race Against Time” to Find Cancers Missed During COVID-19 Pandemic
The COVID-19 pandemic has hindered the early diagnosis and treatment of cancer, and this may have set back cancer outcomes by almost a decade in Europe, a new report suggests.
Bariatric Surgery May Reduce Risk of Pancreatic Cancer in Patients With Obesity
Bariatric surgery may reduce the risk of pancreatic cancer in patients with obesity who are younger than 50 years of age, a study suggests.
Genetic Testing “Should Be Considered” for All Patients With Appendix Cancer
As many as 1 in 10 patients with appendix cancer may carry an inherited gene sequence variation associated with cancer susceptibility, a study suggests.
Elahere Granted Accelerated Approval for Platinum-Resistant Ovarian Cancer
The approval was based on data from the SORAYA trial.
GSK: Zejula Use for Second-Line Maintenance Treatment Restricted
The decision to restrict the indication follows an FDA review of the phase 3 ENGOT-OV16/NOVA trial.
Repeat TURBT Before RC Does Not Improve Bladder Cancer Outcomes
Study results suggest that tumor debulking does not benefit patients undergoing radical cystectomy.
New Health Problems Post-COVID-19 Also Seen in Children, Teens
Common symptoms occurring 3 or more months after SARS-CoV-2 infection differ between adults and children/adolescents.
Up to 10% of Early-Onset mCRC Cases May Be Driven by Undiagnosed IBD
As many as 10% of early-onset metastatic colorectal cancer cases may be attributable to undiagnosed inflammatory bowel disease, a study suggests.
Dose-Dense Adjuvant Chemotherapy “Optimal” for High-Risk Early Breast Cancer
Dose-dense adjuvant chemotherapy improves disease-free survival in high-risk early breast cancer, according to updated results from the GIM2 trial.
Predicting Outcomes in NSCLC Patients Treated With Immunotherapy or Immunochemotherapy
Researchers have identified factors associated with survival outcomes in NSCLC patients treated with immunotherapy or immunochemotherapy.
Lenalidomide Associated With Second Primary Malignancies in MM, Not Other Cancers
Lenalidomide increases the risk of developing a second primary malignancy in patients with multiple myeloma, a meta-analysis suggests.
Cytoreductive Nephrectomy Added to ICI Therapy Ups Survival in mRCC
Use of cytoreductive nephrectomy with an immune checkpoint inhibitor reduced the risk of death by 67%.
Acupuncture Reduces Aromatase Inhibitor-Related Joint Pain in Breast Cancer Patients
Acupuncture can reduce aromatase inhibitor-related joint pain in women with early breast cancer, a study suggests.
Adjuvant Abemaciclib Improves iDFS, DRFS in High-Risk Early Breast Cancer
Adding abemaciclib to adjuvant endocrine therapy improves outcomes in patients with high-risk early breast cancer, data suggest.
Isatuximab Plus RVd Dubbed New Standard Care in Newly Diagnosed Multiple Myeloma
Adding isatuximab to RVd improves the rate of MRD negativity in patients with newly diagnosed, transplant-eligible multiple myeloma, a phase 3 trial suggests.
Atezolizumab Plus R-CHOP Deemed Unworthy of Additional Study in Diffuse Large B-Cell Lymphoma
Results of a phase 1/2 trial suggest the combination of atezolizumab and R-CHOP does not warrant further study in DLBCL, according to researchers.
Imjudo Plus Imfinzi and Chemotherapy Approved for Metastatic NSCLC
The approval was based on data from the phase 3 POSEIDON study.
Adcetris Approved for Pediatric Patients With High-Risk Classical Hodgkin Lymphoma
The approval was based on data from the open-label phase 3 AHOD1331 trial.
FDA Authorizes Emergency Use of Kineret for Certain Hospitalized COVID-19 Patients
The authorization was supported by data from the phase 3 SAVE-MORE trial.
Duration of ET Tied to Benefit in DCIS, but Young Patients May Reject ET
Two new studies shed light on the complexity of preventing subsequent breast cancer events in patients with ductal carcinoma in situ.
YouTube, TikTok Videos Don’t Provide Quality Information on Prostate Cancer Screening
None of the YouTube or TikTok videos analyzed contained both high-quality and accurate information on prostate cancer screening.
No Difference in OS With Margetuximab vs Trastuzumab in HER2+ Breast Cancer
Margetuximab does not provide an overall survival benefit over trastuzumab in patients with previously treated, HER2-positive breast cancer, a phase 3 trial suggests.
Oncology Hospitalists Improve Readmission Rates and Discharge to Hospice
The use of oncology hospitalists can reduce readmission rates and improve discharge to hospice, a study suggests.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Loading... 
Loading...